Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Braz. j. med. biol. res ; 40(5): 707-712, May 2007. tab, graf
Article in English | LILACS | ID: lil-449092

ABSTRACT

Water deprivation-induced thirst is explained by the double-depletion hypothesis, which predicts that dehydration of the two major body fluid compartments, the extracellular and intracellular compartments, activates signals that combine centrally to induce water intake. However, sodium appetite is also elicited by water deprivation. In this brief review, we stress the importance of the water-depletion and partial extracellular fluid-repletion protocol which permits the distinction between sodium appetite and thirst. Consistent enhancement or a de novo production of sodium intake induced by deactivation of inhibitory nuclei (e.g., lateral parabrachial nucleus) or hormones (oxytocin, atrial natriuretic peptide), in water-deprived, extracellular-dehydrated or, contrary to tradition, intracellular-dehydrated rats, suggests that sodium appetite and thirst share more mechanisms than previously thought. Water deprivation has physiological and health effects in humans that might be related to the salt craving shown by our species.


Subject(s)
Animals , Humans , Rats , Appetite/physiology , Drinking Behavior/physiology , Homeostasis/physiology , Thirst/physiology , Water Deprivation/physiology , Sodium Chloride
2.
Braz J Med Biol Res ; 40(5): 707-12, 2007 May.
Article in English | MEDLINE | ID: mdl-17464434

ABSTRACT

Water deprivation-induced thirst is explained by the double-depletion hypothesis, which predicts that dehydration of the two major body fluid compartments, the extracellular and intracellular compartments, activates signals that combine centrally to induce water intake. However, sodium appetite is also elicited by water deprivation. In this brief review, we stress the importance of the water-depletion and partial extracellular fluid-repletion protocol which permits the distinction between sodium appetite and thirst. Consistent enhancement or a de novo production of sodium intake induced by deactivation of inhibitory nuclei (e.g., lateral parabrachial nucleus) or hormones (oxytocin, atrial natriuretic peptide), in water-deprived, extracellular-dehydrated or, contrary to tradition, intracellular-dehydrated rats, suggests that sodium appetite and thirst share more mechanisms than previously thought. Water deprivation has physiological and health effects in humans that might be related to the salt craving shown by our species.


Subject(s)
Appetite/physiology , Drinking Behavior/physiology , Homeostasis/physiology , Thirst/physiology , Water Deprivation/physiology , Animals , Humans , Rats , Sodium Chloride
3.
Ann Clin Biochem ; 44(Pt 1): 63-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17270094

ABSTRACT

BACKGROUND: We present new findings on liver steatosis detected in a group of 20 morbidly obese patients who were reassessed shortly after bariatric surgery (BS) by assaying hepatic markers in their serum. METHODS: We assayed aspartate aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase (gamma-GT), cholinesterase, cholesterol, total protein, and albumin, and measured the weight and the body mass index (BMI) of patients, before and one and three months after surgery. RESULTS: There were significant reductions in BMI following surgery and also falls in transaminases and gamma-GT activities three months after BS. No changes occurred in other parameters between periods, except that cholesterol was above reference values before BS and fell to normal levels three months after BS. CONCLUSIONS: We suggest that before undergoing surgery, the patients suffered from slight steatosis, while after BS the reduction in AST and gamma-GT indicated that this condition was corrected within three months. Moreover, these enzymes may be useful markers for excess fat in the liver.


Subject(s)
Bariatric Surgery , Fatty Liver/blood , Obesity, Morbid/pathology , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Aspartate Aminotransferases/blood , Bilirubin/blood , Biomarkers/blood , Cholinesterases/blood , Female , Follow-Up Studies , Humans , L-Lactate Dehydrogenase/blood , Male , Multivariate Analysis , Obesity, Morbid/complications , Obesity, Morbid/surgery , Postoperative Period , Retrospective Studies , Treatment Outcome , gamma-Glutamyltransferase/blood
4.
J Ethnopharmacol ; 96(1-2): 43-8, 2005 Jan 04.
Article in English | MEDLINE | ID: mdl-15588649

ABSTRACT

The fruit of Indian Eugenia jambolana have been shown to have therapeutic properties, but because the therapeutic potential of a plant is related to the geographic region in which the plant was grown and to the part of the plant used, we investigated Brazilian Eugenia jambolana fruit using the same preparation and experimental methods as have been used in India. The well-established metabolic cage model was used to evaluate the physiological and metabolic parameters associated with streptozotocin-induced diabetes in rats (n=10) which had been administered, by gavage, 50 mg per day of lyophilised Eugenia jambolana fruit-pulp extract for 41 days. We found that, compared to untreated controls, rats treated with the lyophilised fruit-pulp showed no observable difference in body weight, food or water intake, urine volume, glycaemia, urinary urea and glucose, hepatic glycogen, or on serum levels of total cholesterol, HDL cholesterol or triglycerides. No change was observed in the masses of epididymal or retroperitoneal adipose tissue or of soleus or extensor digitorum longus muscles. This lack of any apparent effect on the diabetes may be attributable to the regional ecosystem where the fruit was collected and/or to the severity of the induced diabetes.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Fruit , Hypoglycemic Agents/pharmacology , Phytotherapy , Syzygium , Adipose Tissue/drug effects , Adipose Tissue/pathology , Animals , Blood Glucose/drug effects , Body Weight/drug effects , Diabetes Mellitus, Experimental/chemically induced , Epididymis/drug effects , Epididymis/pathology , Glycosuria/drug therapy , Hypoglycemic Agents/therapeutic use , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/pathology , Organ Size/drug effects , Plant Preparations/pharmacology , Plant Preparations/therapeutic use , Rats , Streptozocin , Time Factors
5.
Braz. j. med. biol. res ; 36(10): 1327-1332, Oct. 2003. ilus, tab
Article in English | LILACS | ID: lil-346482

ABSTRACT

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder due to an inborn error of cholesterol metabolism, characterized by congenital malformations, dysmorphism of multiple organs, mental retardation and delayed neuropsychomotor development resulting from cholesterol biosynthesis deficiency. A defect in 3ß-hydroxysteroid-delta7-reductase (delta7-sterol-reductase), responsible for the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol, causes an increase in 7-DHC and frequently reduces plasma cholesterol levels. The clinical diagnosis of SLOS cannot always be conclusive because of the remarkable variability of clinical expression of the disorder. Thus, confirmation by the measurement of plasma 7-DHC levels is needed. In the present study, we used a simple, fast, and selective method based on ultraviolet spectrophotometry to measure 7-DHC in order to diagnose SLOS. 7-DHC was extracted serially from 200 æl plasma with ethanol and n-hexane and the absorbance at 234 and 282 nm was determined. The method was applied to negative control plasma samples from 23 normal individuals and from 6 cases of suspected SLOS. The method was adequate and reliable and 2 SLOS cases were diagnosed


Subject(s)
Child, Preschool , Humans , Male , Infant , Child , Cholesterol , Dehydrocholesterols , Smith-Lemli-Opitz Syndrome/diagnosis , Biomarkers , Smith-Lemli-Opitz Syndrome/blood , Spectrophotometry, Ultraviolet
6.
Braz J Med Biol Res ; 36(10): 1327-32, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14502364

ABSTRACT

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder due to an inborn error of cholesterol metabolism, characterized by congenital malformations, dysmorphism of multiple organs, mental retardation and delayed neuropsychomotor development resulting from cholesterol biosynthesis deficiency. A defect in 3 -hydroxysteroid-delta7-reductase (delta7-sterol-reductase), responsible for the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol, causes an increase in 7-DHC and frequently reduces plasma cholesterol levels. The clinical diagnosis of SLOS cannot always be conclusive because of the remarkable variability of clinical expression of the disorder. Thus, confirmation by the measurement of plasma 7-DHC levels is needed. In the present study, we used a simple, fast, and selective method based on ultraviolet spectrophotometry to measure 7-DHC in order to diagnose SLOS. 7-DHC was extracted serially from 200 l plasma with ethanol and n-hexane and the absorbance at 234 and 282 nm was determined. The method was applied to negative control plasma samples from 23 normal individuals and from 6 cases of suspected SLOS. The method was adequate and reliable and 2 SLOS cases were diagnosed.


Subject(s)
Cholesterol/blood , Dehydrocholesterols/blood , Smith-Lemli-Opitz Syndrome/diagnosis , Biomarkers/blood , Child , Child, Preschool , Humans , Infant , Male , Smith-Lemli-Opitz Syndrome/blood , Spectrophotometry, Ultraviolet
7.
Arch. latinoam. nutr ; 53(1): 47-51, mar. 2003.
Article in Portuguese | LILACS | ID: lil-356588

ABSTRACT

This study was undertaken to verify the effect of a daily intake of a new fermented soy milk produced with Enterococcus faecium and Lactobacillus jugurti on the serum lipid levels in normocholesterolemic middle-aged men. The study was randomized, double-blind and placebo-controlled and was performed for a period of 6 weeks. Forty-four normocholesterolemic healthy, male volunteers, aged 40-55 years old were randomly separated in two groups: The F-group received 200 ml of the fermented product daily and the P-group received 200 ml of placebo (chemically fermented). The blood samples were drawn initially and after 3 and 6 weeks and serum values for total cholesterol, HDL-cholesterol and triglyceride were determined. The LDL-cholesterol value was estimated. No significant changes in the fermented group (F) were observed for total cholesterol, LDL-cholesterol or triglyceride levels, while the HDL-cholesterol level was significantly higher (p < or = 0.05) after 6 weeks. The total cholesterol and LDL-cholesterol levels were significantly higher (p < or = 0.05) in the placebo group (P), but no changes were found for the HDL-cholesterol and triglyceride levels during the experimental period. In conclusion, the intake of 200 ml/day of the fermented soy milk, produced with E. faecium and L. jugurti, for 6 weeks, did not affect the serum total cholesterol and LDL-cholesterol, and led an increase of 10 per cent in the HDL-cholesterol level.


Subject(s)
Humans , Male , Adult , Middle Aged , Cholesterol/blood , Glycine max , Yogurt , Arteriosclerosis/etiology , Arteriosclerosis/prevention & control , Cholesterol, HDL , Cholesterol, LDL , Cholesterol/metabolism , Double-Blind Method , Eating , Enterococcus faecium , Fermentation , Lactobacillus , Lipids/blood , Lipids/metabolism , Risk Factors , Triglycerides/blood
8.
Braz J Med Biol Res ; 35(9): 1069-74, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12219178

ABSTRACT

Losartan, an AT1 angiotensin II (ANG II) receptor non-peptide antagonist, induces an increase in mean arterial pressure (MAP) when injected intracerebroventricularly (icv) into rats. The present study investigated possible effector mechanisms of the increase in MAP induced by icv losartan in unanesthetized rats. Male Holtzman rats (280-300 g, N = 6/group) with a cannula implanted into the anterior ventral third ventricle received an icv injection of losartan (90 micro g/2 micro l) that induced a typical peak pressor response within 5 min. In one group of animals, this response to icv losartan was completely reduced from 18 +/- 1 to 4 +/- 2 mmHg by intravenous (iv) injection of losartan (2.5-10 mg/kg), and in another group, it was partially reduced from 18 +/- 3 to 11 +/- 2 mmHg by iv prazosin (0.1-1.0 mg/kg), an alpha1-adrenergic antagonist (P<0.05). Captopril (10 mg/kg), a converting enzyme inhibitor, injected iv in a third group inhibited the pressor response to icv losartan from 24 +/- 3 to 7 +/- 2 mmHg (P<0.05). Propranolol (10 mg/kg), a beta-adrenoceptor antagonist, injected iv in a fourth group did not alter the pressor response to icv losartan. Plasma renin activity and serum angiotensin-converting enzyme activity were not altered by icv losartan in other animals. The results suggest that the pressor effect of icv losartan depends on angiotensinergic and alpha1-adrenoceptor activation, but not on increased circulating ANG II.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Hypertension/blood , Losartan/pharmacology , Peptidyl-Dipeptidase A/blood , Renin/blood , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/antagonists & inhibitors , Blood Pressure/drug effects , Hypertension/chemically induced , Injections, Intraventricular , Losartan/administration & dosage , Losartan/antagonists & inhibitors , Male , Radioimmunoassay , Rats , Rats, Sprague-Dawley
9.
Braz. j. med. biol. res ; 35(9): 1069-1074, Sept. 2002. tab, graf
Article in English | LILACS | ID: lil-325902

ABSTRACT

Losartan, an AT1 angiotensin II (ANG II) receptor non-peptide antagonist, induces an increase in mean arterial pressure (MAP) when injected intracerebroventricularly (icv) into rats. The present study investigated possible effector mechanisms of the increase in MAP induced by icv losartan in unanesthetized rats. Male Holtzman rats (280-300 g, N = 6/group) with a cannula implanted into the anterior ventral third ventricle received an icv injection of losartan (90 æg/2 æl) that induced a typical peak pressor response within 5 min. In one group of animals, this response to icv losartan was completely reduced from 18 ± 1 to 4 ± 2 mmHg by intravenous (iv) injection of losartan (2.5-10 mg/kg), and in another group, it was partially reduced from 18 ± 3 to 11 ± 2 mmHg by iv prazosin (0.1-1.0 mg/kg), an alpha1-adrenergic antagonist (P<0.05). Captopril (10 mg/kg), a converting enzyme inhibitor, injected iv in a third group inhibited the pressor response to icv losartan from 24 ± 3 to 7 ± 2 mmHg (P<0.05). Propranolol (10 mg/kg), a ß-adrenoceptor antagonist, injected iv in a fourth group did not alter the pressor response to icv losartan. Plasma renin activity and serum angiotensin-converting enzyme activity were not altered by icv losartan in other animals. The results suggest that the pressor effect of icv losartan depends on angiotensinergic and alpha1-adrenoceptor activation, but not on increased circulating ANG II


Subject(s)
Animals , Male , Rats , Adrenergic alpha-Agonists , Angiotensin-Converting Enzyme Inhibitors , Hypertension , Losartan , Peptidyl-Dipeptidase A , Receptors, Angiotensin , Renin , Captopril , Injections, Intraventricular , Losartan , Prazosin , Propranolol , Radioimmunoassay , Rats, Sprague-Dawley
10.
J Ethnopharmacol ; 81(2): 191-7, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12065150

ABSTRACT

The effects of using Bauhinia forficata leaf decoction (150 g leaf/l water; 35.2+/-7.8 ml/100 g body weight mean daily dose) as a drinking-water substitute for about 1 month on streptozotocin-diabetes (STZ-diabetes) in male Wistar rats were investigated. The physico-metabolic parameters measured were: body weight, food and liquid intake, urinary volume, hepatic glycogen, serum triglycerides and cholesterol, plasma glucose, urinary glucose and urea, and the weight of epididymal and retroperitoneal adipose tissue and soleus and extensor digitorum longus muscles. The STZ-diabetic rats treated with decoction showed a significant reduction in serum and urinary glucose and urinary urea as compared to the STZ-diabetic control, no difference being seen between decoction-treated and -untreated non-diabetic rats. The other physico-metabolic factors showed no changes in treated STZ-diabetic rats. The improvement in carbohydrate metabolism seen in the rats treated with Bauhinia forficata decoction does not appear to be linked to the inhibition of glycogenolysis or the stimulation of glycogenesis nor does it appear to act in a way similar to insulin or the sulfonylureas, although it may act by the inhibition of neoglycogenesis in a manner similar to that of the biguanides.


Subject(s)
Bauhinia , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/therapeutic use , Animals , Diabetes Mellitus, Experimental/blood , Hypoglycemic Agents/isolation & purification , Hypoglycemic Agents/pharmacology , Male , Phytotherapy/methods , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Plant Leaves , Rats , Rats, Wistar
11.
Arq Bras Cardiol ; 74(3): 209-16, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10951824

ABSTRACT

OBJECTIVE: To assess the effect of a new feed soy product fermented by Enterococcus faecium and Lactobacillus jugurti on the serum lipid levels of rabbits with induced hypercholesterolemia. METHODS: Thirty-two rabbits were divided into 4 groups as follows: 1) control (C); 2) hypercholesterolemic (H); 3) hypercholesterolemic + fermented product (HPF); and 4) control + fermented product (CPF). The H and HPF groups were fed with a diet with 0.15% (p/p) cholesterol in the first 15 days. C and CPF groups received regular food preparation. The HPF and CPF groups received 10 mL daily of the fermented 30 days. Blood samples were drawn at the beginning of the study and at the 15th and 30th days. Concentrations of total cholesterol, HDL-cholesterol, and triglycerides were analyzed. RESULTS: After 15 days, the HPF group showed a total cholesterol concentration lower (18.4%) than that of the H group (p = 0.05), but this difference disappeared after 30 days. No change was observed in total cholesterol levels of C and CPF groups. After 15 days, the HDL-cholesterol was higher (17.8%) in the HPF group, but the triglyceride levels remained unchanged in all groups during the same period of time. CONCLUSION: The soy fermented product caused an 18.4% reduction in total cholesterol and a 17.8% increase in the HDL-fraction. It may, therefore, be a possible coadjutor in the treatment of hypercholesterolemia.


Subject(s)
Glycine max/therapeutic use , Hypercholesterolemia/therapy , Lipids/blood , Phytotherapy , Animals , Cholesterol/blood , Enterococcus faecium , Fermentation , Lactobacillus , Male , Rabbits , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...